GlassScriptPhysician profile
Nicholas J Stepanski
NPI 1023547429
$9,156.34
in general payments reported to CMS, 2019-2025
36 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $664 · 2021: $1,666 · 2022: $1,642 · 2023: $1,460 · 2024: $1,481 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,409.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,737.84 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $901.02 | 2019-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $898.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $856.78 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $827.82 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $585.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $508.46 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Ironwood Pharmaceuticals, INC | $285.83 | 2021-2024 | Linzess |
| Amarin Pharma, INC. | $269.23 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $235.27 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.87 | 2021-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $194.38 | 2022-2025 | Eliquis |
| Allergan, INC. | $180.16 | 2019-2020 | |
| Abbott Laboratories | $149.25 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Nestle Healthcare Nutrition INC. | $139.99 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $121.50 | 2021-2025 | Veozah |
| Amgen INC. | $111.52 | 2021-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $99.24 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $97.09 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $94.33 | 2022 | |
| Exact Sciences Corporation | $92.27 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $73.61 | 2020-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $68.19 | 2022-2024 | |
| Eisai INC. | $67.50 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $55.20 | 2022-2023 | |
| Adlon Therapeutics L.P. | $55.07 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $43.38 | 2020-2021 | |
| Dexcom, INC. | $43.04 | 2024-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $26.61 | 2021-2022 | |
| Pulmonx Corporation | $23.21 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Phadia US INC. | $22.91 | 2024 | Immunocap |
| Ibsa Pharma INC. | $16.50 | 2024 | Tirosint, Licart |
| Bardy Diagnostics, INC. | $16.23 | 2021 | |
| Corcept Therapeutics | $16.15 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $12.28 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Stepanski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.